TECH has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TECH has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Bio-Techne's Other Operating Expense for the three months ended in Dec. 2023 was $0 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 was $34 Mil.
Bio-Techne's quarterly Other Operating Expense declined from Jun. 2023 ($34 Mil) to Sep. 2023 ($0 Mil) but then stayed the same from Sep. 2023 ($0 Mil) to Dec. 2023 ($0 Mil).
Bio-Techne's annual Other Operating Expense increased from Jun. 2021 ($30 Mil) to Jun. 2022 ($35 Mil) but then declined from Jun. 2022 ($35 Mil) to Jun. 2023 ($34 Mil).
The historical data trend for Bio-Techne's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $34 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Bio-Techne's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.
Roeland Nusse | director | 473 TENNESSEE, PALO ALTO CA 94306 |
William Geist | officer: PRESIDENT, PROTEIN SCIENCES | 900 MIDDLESEX TURNPIKE, C/O QUANTERIX CORPORATION, BILLERICA MA 01821 |
Charles R. Kummeth | director, officer: Chief Executive Officer | 425 MARTINGALE ROAD, SUITE 1000, SCHAUMBURG IL 60173-2213 |
Shane Bohnen | officer: SVP - General Counsel | 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413 |
Brenda S. Furlow | officer: SVP - General Counsel | 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413 |
John L Higgins | director | 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037 |
Robert V Baumgartner | director | 5775 WAYZATA BOULEVARD, SUITE 400, MINNEAPOLIS MN 55416 |
Kim Kelderman | officer: Pres. Diagnostics & Genom | 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413 |
Norman David Eansor | officer: SVP Biotech | 8100 SOUTHPARK WAY, A-8, LITTLETON CO 80120 |
James Hippel | officer: Chief Financial Officer | 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413 |
Joseph D Keegan | director | C/O MOLECULAR DEVICES CORP, 1311 ORLEANS DRIVE, SUNNYVALE CA 94089 |
Alpna Seth | director | 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413 |
Julie L Bushman | director | 185 SOUTH 84TH STREET, SUITE 200, MILWAUKEE WI 53214 |
Rupert Vessey | director | C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901 |
Randolph C Steer | director | 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413 |
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.